A synthetic BBB-permeable tripeptide GCF confers neuroprotection by increasing glycine in the ischemic brain

Juan Chen, Yang Zhuang, Ya Zhang, Huabao Liao, Rui Liu, Jing Cheng, Zhifeng Zhang, Jiangdong Sun, Jingchen Gao, Xiyuran Wang, Shujun Chen, Liang Zhang, Fengyuan Che, Qi WanFrontiers in Pharmacology 2022 · DOI

TL;DR

Researchers have developed a novel tripeptide, GCF, that effectively crosses the blood-brain barrier (BBB) and delivers glycine to the ischemic brain. This GCF-mediated delivery of glycine shows significant neuroprotection in a rat model of stroke, offering a promising new therapeutic strategy for acute ischemic stroke.

What Problem Does This Paper Address?

Cerebral ischemia-reperfusion injury, commonly known as stroke, is a leading cause of death and disability. Glycine, a simple amino acid, has demonstrated neuroprotective properties in both in vitro and in vivo models of stroke. However, its therapeutic application is severely limited by its poor permeability across the blood-brain barrier (BBB). This critical barrier prevents most drugs from reaching the brain effectively, posing a major challenge in the development of treatments for neurological disorders. The paper addresses this challenge by designing a novel peptide that can overcome the BBB and deliver a therapeutic agent (glycine) to the site of injury.

Methods

The researchers designed a tripeptide, H-glycine-cysteine-phenylalanine-OH (GCF), with specific modifications to enhance BBB permeability and glycine delivery.

  • BBB Permeability Enhancement: Phenylalanine was incorporated into the tripeptide to leverage its known high BBB permeability.
  • Glycine Delivery Mechanism: Cysteine was conjugated with glycine, designed to be cleavable within the brain, thereby releasing glycine at the target site.
  • Distribution and Level Measurement: Immunofluorescence labeling (using FITC-conjugated GCF) and High-Performance Liquid Chromatography (HPLC) were employed to track the distribution of GCF in the brain and quantify glycine levels.
  • Neuroprotection Evaluation: Standard assays were used to assess the protective effects of GCF:
  • TTC Staining: To measure infarct volume (area of dead tissue).
  • LDH Release Assay: To quantify cell damage (lactate dehydrogenase is released from damaged cells).
  • MTT Assay: To assess cell viability.
  • In Vivo Models: A rat model of middle cerebral artery occlusion (MCAO) was used to induce ischemia-reperfusion injury.
  • In Vitro Models: Cultured cortical neurons were subjected to oxygen-glucose deprivation (OGD) to mimic ischemic conditions.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • Glycine's BBB Challenge: The study confirms that delivering glycine directly to the brain in therapeutic amounts requires extremely high doses, highlighting its poor BBB permeability in ischemic conditions.
  • GCF as a BBB Shuttle and Prodrug: The tripeptide GCF acts as a dual-function molecule: it efficiently crosses the BBB (shuttle) and then releases glycine (prodrug) to exert its therapeutic effect. This is a novel approach compared to peptides that directly interfere with signaling pathways.
  • Phenylalanine's Role in BBB Permeation: The inclusion of phenylalanine is crucial for GCF's ability to penetrate the BBB, as demonstrated by its distribution in brain tissue.
  • Cysteine Linker for Glycine Release: The cleavable cysteine-glycine bond is essential for GCF to function as a prodrug, releasing active glycine in the ischemic brain. The non-cleavable acetyl-GCF derivative failed to increase glycine levels or provide neuroprotection.
  • Oligopeptide Transporter Involvement: Evidence suggests that the oligopeptide transporter PhT1 plays a role in GCF's transport across the BBB.
  • Intranasal Delivery Potential: Preliminary findings suggest intranasal administration of GCF might also be effective, opening avenues for pre-hospital stroke treatment.

Key Results

  • GCF Penetrates BBB: FITC-labeled GCF was found distributed in both ischemic and sham rat brains, with higher concentrations in the ischemic regions and specifically within neurons.
  • Increased Glycine Levels: Intravenous GCF injection significantly increased glycine levels in the ischemic brain tissue of rats, peaking between 40 and 120 minutes post-injection.
  • Neuroprotection by GCF:
    • GCF treatment (10, 50, and 150 mg/kg) significantly reduced infarct volume in MCAO rats.
  • In vitro, GCF protected cultured neurons from OGD-induced cell death, as evidenced by reduced LDH release and increased cell viability.
  • Acetyl-GCF Ineffectiveness: The non-cleavable acetyl-GCF derivative did not increase glycine levels, reduce infarct volume, or protect neurons in vitro, underscoring the importance of glycine release.
  • Functional Recovery: GCF treatment improved neurobehavioral outcomes in stroke rats, as measured by reduced mNSS scores, improved beam-walking performance, and enhanced modified sticky-tape test scores.

Limitations and Future Work

  • Specificity of Cleavage: While the study suggests cysteine is cleaved to release glycine, the specific enzymes involved and their precise localization within neurons are not fully elucidated.
  • Optimal Dosing and Timing: Further studies are needed to optimize the dosage and timing of GCF administration for maximum therapeutic benefit.
  • Human Translation: While promising, these results are from animal models. Further research and clinical trials are necessary to determine GCF's efficacy and safety in humans.
  • Broader Applications: The paper suggests that the GCF design could be adapted to deliver other BBB-impermeable amino acids or small molecules for treating various CNS diseases and potentially peripheral organ injuries.
  • Intranasal Delivery: The potential for intranasal delivery warrants further investigation as a convenient and rapid administration route for stroke patients.

Summary updated

Abstract

<b>Background:</b> We and others have previously demonstrated that glycine is neuroprotective in cerebral ischemia-reperfusion injury. But glycine has low permeability to the blood-brain barrier (BBB). To deliver glycine into the ischemic brain to confer neuroprotection, we designed a novel glycine-containing and BBB-permeable tripeptide, the H-glycine-cysteine-phenylalanine-OH (GCF). <b>Methods:</b> For the synthesis of GCF, phenylalanine was included to increase the BBB permeability of the tripeptide. Cysteine was conjugated with glycine to enable the release of glycine from GCF. With the use of immunofluorescence labeling and HPLC assays, we measured the distribution and level of GCF. We used TTC labeling, LDH release, and MTT assays to evaluate the neuroprotective effect of GCF. <b>Results:</b> Following intravenous injection in a rat model of cerebral ischemia-reperfusion injury, GCF was intensively distributed in the ischemic neurons. Intravenous injection of GCF, but not the non-cleavable acetyl-GCF, resulted in the elevation of glycine in the ischemic brain. GCF but not acetyl-GC conferred neuroprotection in ischemic stroke animals. <b>Conclusion:</b> GCF protects against cerebral ischemia-reperfusion injury in the rat. In contrast to peptide drugs that exert therapeutic effect by interfering with signaling interaction, GCF acts as a BBB shuttle and prodrug to deliver glycine to confer neuroprotection, representing a novel therapeutic strategy for acute ischemic stroke.
BibTeX
@inproceedings{chen2022synthetic,
  author = {Juan Chen and Yang Zhuang and Ya Zhang and Huabao Liao and Rui Liu and Jing Cheng and Zhifeng Zhang and Jiangdong Sun and Jingchen Gao and Xiyuran Wang and Shujun Chen and Liang Zhang and Fengyuan Che and Qi Wan},
  title = {{A synthetic BBB-permeable tripeptide GCF confers neuroprotection by increasing glycine in the ischemic brain}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.950376},
}
Figure